AT9283

SIGMA/SML2394 - ≥98% (HPLC)

Synonym: 1-Cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea; AT 9283; AT-9283; N-Cyclopropyl-N′-[3-[6-(4-morpholinylmethyl)-1H-benzimidazol-2-yl]-1H-pyrazol-4-yl]-urea

CAS Number: 896466-04-9
Empirical Formula (Hill Notation): C₁₉H₂₃N₇O₂
Molecular Weight: 381.43
MDL Number: MFCD12031513
Linear Formula: C₁₉H₂₃N₇O₂
Product Type: Chemical

Catalog Number	PKG Qty.	Price


45-SML2394-5MG	5 mg	$97.40 1/EA	Add To Favorites
45-SML2394-25MG	25 mg	$314.00 1/EA	Add To Favorites

Properties
Descriptions
Safety Info.
Basic Data

assay	≥98% (HPLC)
color	white to beige
form	powder
solubility	DMSO: 2 mg/mL, clear
storage temp.	−20°C

Biochem/physiol Actions:

AT9283 has also been shown to accelerate growth arrest in various xenograft models.

Biochem/physiol Actions:

AT9283 is an ATP site-targeting pyrazole-benzimidazole-based molecule with inhibitory potency against multiple kinases, most notably Aurora A/B (IC50 ≤3.0 nM), JAK2/3 (IC50 = 1.2/1.1 nM), Abl T315I (IC50 = 4 nM), GSK3β, FGFR2, VEGFR3 (Flt4), Mer, Ret, Rsk2/3, Tyk2, Yes (IC50 = 1-10 nM). AT9283 also inhibits 72 other kinases/mutations at a reduced potency (IC50 = 10-30 nM against 14, 30-100 nM against 21, 100-300 against 37 targets), while displaying an IC50 >300 nM toward 144 other kinase targets. AT9283 inhibits the growth/survival of multiple solid tumor cell lines in vitro (IC50 = 7.7-20 nM) and shows anti-cancer efficacy in mice via i.p. injection in vivo (67% and 76%HCT116 tumor growth inhibition on day 16, respectively, with 15 and 20 mg/kg b.i.d., two-day on and two-day off; >95% inhibition of Ba/F3 ETV6-JAK2 leukemia proliferation on day 12 with 10 mg/kg b.i.d. on days 2–5 and 8–12).

WGK Germany	WGK 3
Flash Point(F)	Not applicable
Flash Point(C)	Not applicable

Purity	≥98% (HPLC)
Storage Temp.	−20°C
UNSPSC	12352200

To Order From a Quote